What does HRD status mean for Melanoma treatment

HRD Status and Melanoma Treatment

I appreciate your question about HRD (Homologous Recombination Deficiency) status. Let me give you a straightforward answer based on current melanoma treatment guidelines.

The Short Answer

HRD status is not currently a standard biomarker used to guide melanoma treatment decisions. According to the NCCN Guidelines for Patients: Melanoma (2025), the biomarkers that DO matter for melanoma treatment planning are:

• BRAF mutations (V600 mutations specifically)
• PD-L1 expression (for immunotherapy decisions)
• CDKN2A mutations (for genetic risk assessment)

Why HRD Matters in Other Cancers But Not Melanoma

HRD testing is very important for certain cancers—particularly breast cancer, ovarian cancer, and some other tumor types—where it helps doctors decide whether to use PARP inhibitors (drugs that target DNA repair defects). However, melanoma treatment has evolved along a different path.

What DOES Guide Melanoma Treatment

According to NCCN Guidelines, melanoma treatment decisions are based on:

1. BRAF mutation status – If present, targeted therapies like dabrafenib/trametinib may be recommended
2. Stage of disease – Whether melanoma is localized, regional, or metastatic (spread)
3. Immunotherapy response markers – PD-L1 expression helps predict response to checkpoint inhibitors like nivolumab and pembrolizumab
4. Resectability – Whether the tumor can be surgically removed

Questions to Ask Your Care Team

If HRD testing has been mentioned in your case, these questions would be helpful:

1. "Why is HRD testing being recommended for my specific situation?"
2. "What biomarkers are most important for my melanoma treatment plan?"
3. "Have I been tested for BRAF mutations and PD-L1 expression?"
4. "How will these test results change my treatment options?"
5. "Are there any clinical trials that might be relevant to my case?"

Important Context

Melanoma research is constantly evolving. While HRD status isn't currently standard for melanoma, it's possible that new research could change this in the future. Your oncologist may have specific reasons for ordering this test based on your individual case that go beyond standard guidelines.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.